CD8A and neoplasm: CXCL10, a chemokine known for its role in immune cell trafficking, and shown to be upregulated in the tumor following VSV-NDV treatment (Figure 1C), has significant beneficial effects in the TME, particularly in enhancing CD8+ T cell responses [21,22].